Aprea to present at the American Association for Cancer Research (AACR) annual meeting in Washington, DC, in April 2013
STOCKHOLM – April 3, 2013. Aprea AB today announces that a poster entitled “Strong synergistic effects with cisplatin and APR-246, a novel compound reactivating mutant p53, in ovarian cancer cell lines and primary cells from patients” will be presented at the upcoming AACR meeting in Washington, DC, USA, in April 2013. Aprea is a Karolinska Development portfolio company.The poster contains data from preclinical combination studies with APR-246 and platinum compounds. The presentation will take place on Tuesday April 9 between 8.00 AM and 12.00 PM (EST) at the AACR meeting at the Walter E.